Entities / Company
Emergent BioSolutions.
multinational biopharmaceutical company headquartered in Gaithersburg, Maryland, USA
- Reports this week
- 2
- Active events
- 1
- Connections
- 55
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
-
MarketBeat provided analyst ratings and targets for small-cap healthcare companies Emergent BioSolutions and Entrada Therapeutics.Some support2 reports
-
Alnylam Pharmaceuticals (listed on Nasdaq) and Emergent BioSolutions (listed on NYSE) are two healthcare companies competing for investment.Some support1 report
One to three months ago
-
Emergent BioSolutions is being investigated regarding potential securities law violations.Some support1 report
-
Benzinga reported on stock changes for Emergent BioSolutions, and Benchmark reissued a buy rating on the stock.Some support1 report
-
Renaissance Technologies lifted its stake in Emergent BioSolutions on August 7, 2026.Some support1 report
-
CDC reported US overdose death trends and expanding naloxone access, while Emergent BioSolutions acquired rights to KLOXXADO in Canada.Speculative1 report1 development inside
-
Emergent BioSolutions is facing increased competition and pricing pressure in the naloxone market while undergoing restructuring and accelerating government deliveries.Some support1 report
Gone quiet
No new reports in 90+ days-
Emergent BioSolutions and Silo Pharma, Inc. are undergoing a direct comparison of their financial performance metrics.Some support1 report
-
Emergent BioSolutions used LinkedIn and Spotify for public health updates and participated in a Wells Fargo conference.Some support2 reports
-
OTC naloxone is becoming available in the House of Representatives of Thailand to help reduce overdose deaths.Some support1 report
-
FTSE Russell determined its index membership criteria based on market capitalization.Speculative1 report
-
Emergent BioSolutions secured seven biodefense contract modifications from the U.S. Government.Some support3 reports2 developments inside
-
Emergent BioSolutions supports the U.S. smallpox preparedness strategy.Speculative1 report
-
Mental Health America released a report analyzing national overdose data, coinciding with an activation hosted by Ready to Rescue near Chicago.Some support1 report
-
Emergent BioSolutions received a contract modification from BARDA to supply a vaccine, which had previously been approved by the FDA.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Emergent BioSolutions this week
News at the entities that move Emergent BioSolutions most-
Department of Health & Human Services TransactionalThe Trump administration utilized the Department of Health & Human Services for an AI tool.Moves Emergent BioSolutions
-
MarketBeat OperationalApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Emergent BioSolutions
-
Alnylam Pharmaceuticals OperationalAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves Emergent BioSolutions
-
Renaissance Technologies TransactionalRenaissance Technologies holds a significant stake in Lite Strategy, Inc., whose stock trades on the Nasdaq exchange.Moves Emergent BioSolutions
-
Benchmark TransactionalMarketBeat published a buy rating and target price increase for a company, with disclosures made under a Rule 10b5-1 trading plan.Moves Emergent BioSolutions
-
LinkedIn Mentioned togetherBoth LinkedIn and Google are currently being utilized as platforms for news distribution.Moves Emergent BioSolutions
Connections
The 11 strongest of 55, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
MarketBeat Operational
Emergent BioSolutions uses MarketBeat's platform to access analyst recommendations.
-
Alnylam Pharmaceuticals Operational
Both companies are actively competing for investment within the healthcare sector.
-
Department of Health & Human Services Transactional
Emergent BioSolutions receives contracts from the Department of Health & Human Services.
-
Renaissance Technologies Transactional
Renaissance Technologies lifted its stake in Emergent BioSolutions.
-
Nasdaq Shared context
Emergent BioSolutions is a publicly listed company operating within the financial market context.
-
Benzinga Mentioned together
Benzinga provides financial reporting and coverage regarding Emergent BioSolutions' stock performance.
-
Seattle Shared context
Emergent BioSolutions operates within the geographical and regulatory context of Seattle, evidenced by a major corporate spin-off.
-
Gaithersburg Shared context
Emergent BioSolutions is located in Gaithersburg, where it conducts its operations.
Show all 11 connections
-
LinkedIn Mentioned together
Emergent BioSolutions utilizes LinkedIn as a platform for public health communication and mission updates.
-
company Transactional
The relationship is currently under investigation regarding potential securities law violations.
-
Benchmark Transactional
Benchmark issued a buy rating on the stock of Emergent BioSolutions.
History
Events by the month they beganSeptember 2026
3 events- Emergent BioSolutions and Precigen are two healthcare companies that are currently competing for investment.
- MarketBeat provided analyst ratings and targets for small-cap healthcare companies Emergent BioSolutions and Entrada Therapeutics.
- Alnylam Pharmaceuticals (listed on Nasdaq) and Emergent BioSolutions (listed on NYSE) are two healthcare companies competing for investment.
August 2026
4 events- Emergent BioSolutions is being investigated regarding potential securities law violations.
- Benzinga reported on stock changes for Emergent BioSolutions, and Benchmark reissued a buy rating on the stock.
- Renaissance Technologies lifted its stake in Emergent BioSolutions on August 7, 2026.
- Emergent BioSolutions is facing increased competition and pricing pressure in the naloxone market while undergoing restructuring and accelerating government deliveries.
June 2026
9 events- CDC reported US overdose death trends and expanding naloxone access, while Emergent BioSolutions acquired rights to KLOXXADO in Canada.
- Emergent BioSolutions and Silo Pharma, Inc. are undergoing a direct comparison of their financial performance metrics.
- Emergent BioSolutions used LinkedIn and Spotify for public health updates and participated in a Wells Fargo conference.
- OTC naloxone is becoming available in the House of Representatives of Thailand to help reduce overdose deaths.
- FTSE Russell determined its index membership criteria based on market capitalization.
- Emergent BioSolutions secured seven biodefense contract modifications from the U.S. Government.
- Emergent BioSolutions supports the U.S. smallpox preparedness strategy.
- Mental Health America released a report analyzing national overdose data, coinciding with an activation hosted by Ready to Rescue near Chicago.
- Emergent BioSolutions received a contract modification from BARDA to supply a vaccine, which had previously been approved by the FDA.